AlenCiken

Reduced recovery time in mild-to-moderate COVID-19 patients

NASDAQ:CDXC   ChromaDex Corporation
New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients

New Phase 3 study results show added nutritional protocol reduces recovery time in mild-to-moderate COVID-19 patients

The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish standard of care not only reduced recovery time but improved liver health and decreased levels of inflammatory markers.

finance.yahoo.com/ne...finds-113000203.html

Feragatname

Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.